Immodulon is an independent biopharmaceutical company pioneering immunotherapy treatments, in particular for cancer.

Immunotherapy is now recognised as the biggest breakthrough since chemotherapy in the treatment of cancer. Immodulon’s research demonstrates that its lead product is improving the overall outcome for patients when used in combination with other anti-cancer treatments.

Learn more

Our Work

IMM-101

IMM‑101 is a naturally derived investigational medicinal product that helps the body’s immune system to recognise and control cancer. It is intended to be used in combination with other anti-cancer treatments to improve the overall outcome for patients. Clinical studies have produced encouraging increases in survival data in patients with pancreatic cancer and advanced melanoma.

Investors

Immodulon is an independent biopharmaceutical company that has attracted significant investment to date, exclusively from private investors.
All news